



# GLAND PHARMA LIMITED

November 20, 2023

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex  
Bandra (East), Mumbai - 400 051  
Symbol : GLAND (ISIN : INE068V01023)

Dear Sir/Madam,

## **Sub: Reappointment of Independent Director of the Company**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and in continuation to our intimation dated October 17, 2023; We would like to inform that the shareholders of the Company through postal ballot (e-voting) had reappointed Mr. Satyanarayana Murthy Chavali (DIN:00142138) as an Independent Director for another term of five years with effect from 20<sup>th</sup> November, 2023, and approved payment of Commission on profits as remuneration to him.

The voting results and the Scrutinizer's report on the Postal ballot e-voting was already filed with the Stock Exchanges.

We also confirm that the Director reappointed is not debarred from holding the office of Director pursuant to any order of the SEBI or any such other Authority.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in Annexure-A enclosed herewith.

This is for your information and records.

**Yours truly,  
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi  
Company Secretary and Compliance Officer**

Encl: As mentioned above.

**Annexure A**

**Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

**Details of Mr. Satyanarayana Murthy Chavali**

<b>SI. No</b>	<b>Particulars</b>	<b>Remarks</b>
1	Reason for change & Date of Change	<p>The tenure of Mr. Satyanaryana Murthy Chavali as an Independent Director was completed on 19<sup>th</sup> November, 2023. Hence, the Board on 17<sup>th</sup> October, 2023 had reappointed Mr. Satyanarayana Murthy Chavali as an Independent Director for another term of five years with effect from 20<sup>th</sup> November, 2023, subject to the approval of shareholders.</p> <p>The Shareholders through a postal ballot e-voting had passed a special resolution reappointing Mr. Satyanarayana Murthy Chavali as an Independent Director for another term of five years with effect from 20<sup>th</sup> November, 2023 and approved payment of Commission on profits as remuneration to him.</p>
2.	Brief profile	<p>Mr. Satyanarayan Murthy Chavali worked at various leadership roles, a substantial portion in globally focused Pharma / R&amp;D (drug discovery/clinical development) business. He has rich experience in Venture financing and Investment Banking.</p> <p>He is a director on the Board of Directors of Vijaya Diagnostic Centre Limited. He is also the Founder &amp; CEO of SatyaRx Pharma Innovations Private Limited, a drug discovery biotech Company.</p> <p>Mr. C.S.N. Murthy was associated with Aurigene Discovery Technologies Limited (currently Aurigene Oncology Limited) as the Chief Executive Officer. He was associated with ICICI Ventures and had his own boutique firm of Investment Banking during 1990-2000.</p> <p>Mr. Satyanarayana Murthy Chavali holds a bachelor's degree in technology from Indian Institute of Technology, Madras (Chennai) and a post graduate diploma in management from Indian Institute of Management, Bangalore.</p>
3	Disclosure of relationships between director	Not related to any other director or KMP of the Company